Pathogens and autoantigens recognized by pooled human Immunoglobulin G (IVIG targets)

Pathogens and autoantigens recognized by pooled human Immunoglobulin G (IgG) represent a vast and heterogeneous collection of molecular targets addressed by Intravenous Immunoglobulin (IVIG) therapy. These targets encompass a broad spectrum of microbial antigens, including proteins and polysaccharides from bacteria such as Streptococcus pyogenes and viruses like CMV and SARS-CoV-2, as well as diverse self-antigens involved in autoimmune pathogenesis (NIH, 2015; NIH, 2024). Pooled IgG is manufactured from the plasma of thousands of healthy donors, providing a diverse repertoire of antibodies that can neutralize toxins, opsonize pathogens for phagocytosis, and interfere with the activity of pathogenic autoantibodies through anti-idiotypic interactions (NIH, 2003; NIH, 2018). In addition to direct neutralization, the interaction of pooled IgG with these targets modulates the immune system by blocking Fc receptors on macrophages, inhibiting complement-mediated damage, and regulating cytokine production (NIH, 2003). This multi-target approach is clinically utilized to provide passive immunity in primary immunodeficiencies and to restore immune homeostasis in inflammatory conditions like Kawasaki disease and immune thrombocytopenia (NIH, 2023). Despite its broad efficacy, therapeutic intervention against these targets carries risks such as infusion-related reactions, thromboembolic events, and rare cases of aseptic meningitis (Primary Immune Foundation, 2023; ResearchGate, 2024).

Other names

IVIG targetsPooled IgG-bound antigensPolyvalent immunoglobulin targetsMicrobial and self-antigens recognized by pooled IgG

Neutralization of pathogens and toxins, opsonization for phagocytosis, blockade of Fc receptors (FcγR), neutralization of autoantibodies via anti-idiotypic antibodies, inhibition of complement-mediated damage, and saturation of FcRn to accelerate autoantibody catabolism (NIH, 2003; NIH, 2024).